Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation

Glucocorticoid (GC) resistance is a crucial determinant of inferior response to chemotherapy in pediatric acute lymphoblastic leukemia (ALL); however, molecular mechanisms underlying this phenomenon are poorly understood. Deregulated splicing is a common feature of many cancers, which impacts drug response and constitutes an attractive therapeutic target. Therefore, the aim of the current study was to characterize global splicing profiles associated with GC resistance and determine whether splicing modulation could serve as a novel therapeutic option for GC-resistant patients. To this end, 38 primary ALL samples were profiled using RNA-seq-based differential splicing analysis. The impact of splicing modulators was investigated in GC-resistant leukemia cell lines and primary leukemic specimens. Our findings revealed, for the first time, markedly distinct splicing landscapes in ALL samples of B-cell precursor (BCP)-ALL and T-ALL lineages. Differential splicing events associated with GC resistance were involved in RNA processing, a direct response to GCs, survival signaling, apoptosis, cell cycle regulation and energy metabolism. Furthermore, our analyses showed that GC-resistant ALL cell lines and primary samples are sensitive to splicing modulation, alone and in combination with GC. Together, these findings suggest that aberrant splicing is associated with GC resistance and splicing modulators deserve further interest as a novel treatment option for GC-resistant patients.

[1]  Randle Aaron M. Villanueva,et al.  ggplot2: Elegant Graphics for Data Analysis (2nd ed.) , 2019, Measurement: Interdisciplinary Research and Perspectives.

[2]  Jing Zhou,et al.  Alternative splicing of Ikaros regulates the FUT4/LeX-α5β1 integrin-FAK axis in acute lymphoblastic leukemia. , 2019, Biochemical and biophysical research communications.

[3]  E. Giovannetti,et al.  Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma , 2018, EBioMedicine.

[4]  A. Thomas-Tikhonenko,et al.  Exons of Leukemia Suppressor Genes: Creative Assembly Required. , 2018, Trends in cancer.

[5]  Yu-Chiao Chiu,et al.  The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome , 2018, Blood Cancer Journal.

[6]  Matthew R. Gazzara,et al.  Aberrant splicing in B-cell acute lymphoblastic leukemia , 2017, bioRxiv.

[7]  M. Yamaguchi,et al.  Shift in energy metabolism caused by glucocorticoids enhances the effect of cytotoxic anti-cancer drugs against acute lymphoblastic leukemia cells , 2017, Oncotarget.

[8]  J. Delabie,et al.  Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma , 2017, Blood Cancer Journal.

[9]  C. R. Peñafiel,et al.  Clinical significance of the ABCB1 and ABCG2 gene expression levels in acute lymphoblastic leukemia. , 2017 .

[10]  J. Taunton,et al.  JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias , 2017, Leukemia.

[11]  E. Giovannetti,et al.  Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models. , 2016, Journal of visualized experiments : JoVE.

[12]  R. Pieters,et al.  Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[14]  R. Pieters,et al.  Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia , 2016, Leukemia.

[15]  Hedi Peterson,et al.  g:Profiler—a web server for functional interpretation of gene lists (2016 update) , 2016, Nucleic Acids Res..

[16]  S. Armstrong,et al.  Modulation of splicing catalysis for therapeutic targeting of leukemias with spliceosomal mutations , 2016, Nature Medicine.

[17]  G. Peters,et al.  Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance , 2016, International journal of cancer.

[18]  G. Peters,et al.  The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia , 2016, Haematologica.

[19]  Chieh-Yu Liu,et al.  Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia , 2016, Oncotarget.

[20]  D. Teachey,et al.  MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. , 2015, Blood.

[21]  Sarah J. Kurley,et al.  The spliceosome is a therapeutic vulnerability in MYC-driven cancer , 2015, Nature.

[22]  J. Downing,et al.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Koh,et al.  MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis , 2015, Nature.

[24]  Y. Assaraf,et al.  Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance , 2015, Expert opinion on drug metabolism & toxicology.

[25]  D. Lane,et al.  Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response , 2014, Cell Death and Differentiation.

[26]  Jeremiah D. Degenhardt,et al.  Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors , 2013, Haematologica.

[27]  Robert Gentleman,et al.  Software for Computing and Annotating Genomic Ranges , 2013, PLoS Comput. Biol..

[28]  Nam Jin Yoo,et al.  Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors , 2013, International journal of cancer.

[29]  C. Pui,et al.  Relapsed childhood acute lymphoblastic leukaemia. , 2013, The Lancet. Oncology.

[30]  J. Cidlowski,et al.  Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance. , 2013, Endocrine development.

[31]  J. Valcárcel,et al.  The spliceosome as a target of novel antitumour drugs , 2012, Nature Reviews Drug Discovery.

[32]  V. Quesada,et al.  Chronic lymphocytic leukemia with SF3B1 mutation. , 2012, The New England journal of medicine.

[33]  Christopher A. Yarosh,et al.  Alternative splicing networks regulated by signaling in human T cells. , 2012, RNA.

[34]  L. Pasqualucci,et al.  Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.

[35]  M. Relling,et al.  Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. , 2011, Blood.

[36]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[37]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[38]  Qun Pan,et al.  Regulation of alternative splicing by the core spliceosomal machinery. , 2011, Genes & development.

[39]  Christophe Benoist,et al.  Transcriptomes of the B and T Lineages Compared by Multiplatform Microarray Profiling , 2011, The Journal of Immunology.

[40]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[41]  Ronit Vogt Sionov,et al.  Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations , 2010, Leukemia & lymphoma.

[42]  A. Veerman,et al.  IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL , 2010, Leukemia.

[43]  M. Schrappe,et al.  Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  S. Armstrong,et al.  Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. , 2010, Blood.

[45]  G. Escherich,et al.  Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97 , 2010, Leukemia.

[46]  W. Kamps,et al.  Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004 , 2010, Leukemia.

[47]  J. Manley,et al.  Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches , 2009, Nature Reviews Molecular Cell Biology.

[48]  M. Moore,et al.  Meayamycin inhibits pre–messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells , 2009, Molecular Cancer Therapeutics.

[49]  Pornpimol Charoentong,et al.  ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks , 2009, Bioinform..

[50]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[51]  A. Hall,et al.  Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  Ash A. Alizadeh,et al.  Cell-type specific gene expression profiles of leukocytes in human peripheral blood , 2006, BMC Genomics.

[53]  Cheng Cheng,et al.  The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. , 2006, Blood.

[54]  Ulrich Göbel,et al.  Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  J. Cidlowski,et al.  The human glucocorticoid receptor: One gene, multiple proteins and diverse responses , 2005, Steroids.

[56]  R. Lock,et al.  Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. , 2005, Blood.

[57]  Kristen W. Lynch,et al.  Consequences of regulated pre-mRNA splicing in the immune system , 2004, Nature Reviews Immunology.

[58]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[59]  M. D. Den Boer,et al.  Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. , 2003, Blood.

[60]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[61]  A. Borkhardt,et al.  Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. , 1999, Blood.

[62]  R. Pieters,et al.  Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. , 1998, Blood.

[63]  R. Kofler,et al.  Glucocorticoid‐receptor‐gene defects and resistance to glucocorticoid‐induced apoptosis in human leukemic cell lines , 1996, International journal of cancer.

[64]  R. Pieters,et al.  In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. , 1995, Blood.

[65]  R. Pieters,et al.  In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. , 1991, British Journal of Cancer.

[66]  R. Pieters,et al.  In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions , 1990 .

[67]  Jacqueline Cloos,et al.  Cell sensitivity assays: the MTT assay. , 2011, Methods in molecular biology.

[68]  E. Giovannetti,et al.  Analysis of drug interactions. , 2011, Methods in molecular biology.

[69]  Ronit Vogt Sionov,et al.  Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. , 2008, Advances in cancer research.

[70]  W. Tissing,et al.  Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia , 2003, Leukemia.

[71]  B. Shane,et al.  Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure. , 1995, Oncology research.

[72]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[73]  Edinburgh Research Explorer Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A , 2022 .

[74]  Michael J. McGuffin,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .